SOMAÍ launches Soma OG medical cannabis flower in Switzerland

SOMAÍ has introduced its Soma OG medical cannabis flower brand in Switzerland through distribution partner Dascoli Pharma AG. The launch adds three indoor-grown cultivars to the Swiss market and extends the company’s regulated medical cannabis footprint.

Why it matters: - SOMAÍ is expanding its proprietary medical cannabis flower business into Switzerland, a regulated market where access to differentiated cannabinoid products can shape treatment options for healthcare professionals and patients. - The launch also strengthens a long-running distribution partnership and deepens SOMAÍ’s international footprint in regulated medical markets.

What happened: - SOMAÍ announced the launch of Soma OG, its in-house medical cannabis flower brand, in Switzerland on October 6, 2026. - The brand is being introduced through Dascoli Pharma AG, SOMAÍ’s long-standing distribution partner in Switzerland. - The initial launch includes three indoor-grown cultivars: Soap Mints, The Big Apple and Cake & Chem. - Soma OG was cultivated at NovaSoma, SOMAÍ’s indoor cultivation facility in Portugal.

The details: - SOMAÍ describes Soma OG as a brand built to bring carefully selected indoor-grown cultivars to healthcare professionals and patients through compliant supply chains. - The company says each cultivar is selected for its distinct genetic profile and grown under controlled conditions intended to preserve those characteristics from harvest to harvest. - SOMAÍ says the brand combines selected genetics, controlled indoor cultivation and pharmaceutical quality systems for regulated markets. - Dascoli Pharma AG already distributes SOMAÍ’s cannabinoid-based medicines in Switzerland. - Michael Sassano, SOMAÍ founder and interim CEO, said the launch highlights NovaSoma’s cultivation capabilities and SOMAÍ’s commitment to expanding access to high-quality medical cannabis flower through regulated international markets. - Andrew Petronanos, founder and CEO of Dascoli Pharma AG, said the new cultivars strengthen the range of medical cannabis flower options available in Switzerland.

Between the lines: - The launch shows SOMAÍ leaning on vertical integration, pairing cultivation in Portugal with Swiss distribution to push its own branded flower rather than relying only on third-party products. - The move also suggests the company sees flower as a growth driver alongside its existing cannabinoid-based medicines portfolio. - SOMAÍ’s emphasis on pharmaceutical systems and compliance signals a strategy aimed at regulated medical channels, not broader consumer markets.

What's next: - SOMAÍ is likely to keep expanding its proprietary cannabinoid products across regulated medical markets worldwide. - The company says it is continuing to invest in cultivation, pharmaceutical infrastructure and international distribution. - Dascoli Pharma AG will continue serving Swiss healthcare professionals and patients through its wholesale, compounding and nationwide supply operations.

The bottom line: - SOMAÍ is using Switzerland as another launch point for its own medical cannabis flower brand, backed by in-house cultivation in Portugal and an established local distributor.